Susan Carole Lester, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 64 | 2024 | 21163 | 2.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 16 | 2024 | 936 | 1.690 |
Why?
|
| Pathology, Surgical | 5 | 2016 | 150 | 1.640 |
Why?
|
| Nipples | 5 | 2018 | 230 | 1.190 |
Why?
|
| Breast Diseases | 7 | 2024 | 443 | 1.040 |
Why?
|
| Mammography | 23 | 2024 | 2434 | 0.980 |
Why?
|
| Paget's Disease, Mammary | 3 | 2013 | 18 | 0.960 |
Why?
|
| Breast | 14 | 2024 | 1975 | 0.710 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2024 | 1094 | 0.680 |
Why?
|
| Lymph Nodes | 4 | 2022 | 3471 | 0.660 |
Why?
|
| Hyperplasia | 5 | 2021 | 1152 | 0.650 |
Why?
|
| Carcinoma | 3 | 2019 | 2340 | 0.600 |
Why?
|
| Ultrasonography, Mammary | 10 | 2023 | 241 | 0.510 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 216 | 0.500 |
Why?
|
| Dermis | 2 | 2013 | 203 | 0.480 |
Why?
|
| Carcinoma, Lobular | 4 | 2022 | 480 | 0.470 |
Why?
|
| Receptors, Estrogen | 8 | 2023 | 2247 | 0.460 |
Why?
|
| Specimen Handling | 2 | 2009 | 707 | 0.460 |
Why?
|
| Lymphatic Vessels | 1 | 2018 | 356 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 14 | 2024 | 3631 | 0.390 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4785 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 3 | 2018 | 2909 | 0.340 |
Why?
|
| Immunohistochemistry | 15 | 2024 | 11117 | 0.330 |
Why?
|
| Medical Errors | 1 | 2016 | 1263 | 0.310 |
Why?
|
| Biopsy | 9 | 2024 | 6808 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 2180 | 0.270 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 10266 | 0.260 |
Why?
|
| Female | 79 | 2024 | 397050 | 0.260 |
Why?
|
| Fibrocystic Breast Disease | 4 | 2000 | 103 | 0.260 |
Why?
|
| Mastitis | 1 | 2005 | 43 | 0.250 |
Why?
|
| Biopsy, Needle | 9 | 2009 | 1627 | 0.250 |
Why?
|
| Incidental Findings | 2 | 2006 | 697 | 0.220 |
Why?
|
| Sclerosis | 1 | 2024 | 213 | 0.220 |
Why?
|
| Granuloma | 1 | 2005 | 329 | 0.220 |
Why?
|
| Carney Complex | 1 | 2022 | 15 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2011 | 740 | 0.210 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 11254 | 0.200 |
Why?
|
| Myxoma | 1 | 2022 | 114 | 0.200 |
Why?
|
| Humans | 88 | 2024 | 768298 | 0.190 |
Why?
|
| Receptors, Progesterone | 3 | 2010 | 1145 | 0.180 |
Why?
|
| Lymphatic Metastasis | 4 | 2018 | 2924 | 0.180 |
Why?
|
| Neoplasms | 5 | 2023 | 22389 | 0.180 |
Why?
|
| Axilla | 2 | 2022 | 628 | 0.180 |
Why?
|
| Retrospective Studies | 22 | 2024 | 81768 | 0.180 |
Why?
|
| Adult | 42 | 2024 | 223622 | 0.170 |
Why?
|
| Calcinosis | 5 | 2022 | 1482 | 0.170 |
Why?
|
| Middle Aged | 42 | 2024 | 223463 | 0.170 |
Why?
|
| Lymphoma | 2 | 2024 | 1907 | 0.170 |
Why?
|
| World Health Organization | 2 | 2024 | 1327 | 0.170 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2020 | 117 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 802 | 0.160 |
Why?
|
| Clinical Protocols | 3 | 2009 | 1445 | 0.160 |
Why?
|
| Mammaplasty | 2 | 2006 | 1263 | 0.160 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 59683 | 0.150 |
Why?
|
| Aged | 29 | 2024 | 171544 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 1158 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2018 | 3553 | 0.140 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 287 | 0.140 |
Why?
|
| Cyclins | 2 | 1996 | 606 | 0.130 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 376 | 0.130 |
Why?
|
| Diagnosis, Differential | 9 | 2018 | 13019 | 0.130 |
Why?
|
| Fibroma | 1 | 2017 | 201 | 0.130 |
Why?
|
| Phyllodes Tumor | 1 | 2015 | 54 | 0.120 |
Why?
|
| Observer Variation | 5 | 2024 | 2623 | 0.120 |
Why?
|
| Lipoma | 1 | 1996 | 296 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9261 | 0.110 |
Why?
|
| Papilloma | 1 | 2014 | 143 | 0.110 |
Why?
|
| Giant Cell Arteritis | 1 | 2018 | 307 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2011 | 961 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 1997 | 402 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1019 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 828 | 0.100 |
Why?
|
| Receptor, erbB-2 | 4 | 2024 | 2588 | 0.100 |
Why?
|
| Societies, Medical | 5 | 2013 | 3960 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2257 | 0.100 |
Why?
|
| Mass Screening | 1 | 2007 | 5451 | 0.090 |
Why?
|
| Ultrasonography | 6 | 2019 | 6001 | 0.090 |
Why?
|
| Cicatrix | 1 | 2017 | 799 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 212 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 15455 | 0.090 |
Why?
|
| Transformation, Genetic | 2 | 1982 | 194 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1060 | 0.090 |
Why?
|
| Prognosis | 9 | 2019 | 30020 | 0.080 |
Why?
|
| Dog Diseases | 1 | 2010 | 143 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 153 | 0.080 |
Why?
|
| Papilloma, Intraductal | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mastectomy | 3 | 2013 | 1851 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 36849 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 1376 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2524 | 0.070 |
Why?
|
| Stereotaxic Techniques | 3 | 2000 | 556 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2482 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4209 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 3440 | 0.060 |
Why?
|
| X Chromosome | 2 | 1993 | 819 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 18047 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7453 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 9508 | 0.060 |
Why?
|
| Cadherins | 2 | 2022 | 905 | 0.060 |
Why?
|
| Carcinoma in Situ | 2 | 2000 | 789 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 1397 | 0.050 |
Why?
|
| Risk Factors | 6 | 2018 | 74954 | 0.050 |
Why?
|
| Mutation | 3 | 2024 | 30230 | 0.050 |
Why?
|
| Medical Records | 1 | 2009 | 1413 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2240 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 40267 | 0.050 |
Why?
|
| Hybrid Cells | 1 | 1982 | 421 | 0.050 |
Why?
|
| Abscess | 1 | 2005 | 606 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 9433 | 0.050 |
Why?
|
| Neoplasm Proteins | 3 | 2001 | 3609 | 0.050 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 1980 | 7 | 0.040 |
Why?
|
| Pentosyltransferases | 1 | 1980 | 62 | 0.040 |
Why?
|
| United States | 6 | 2013 | 73144 | 0.040 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1980 | 69 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 1274 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 355 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 2011 | 575 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2018 | 65365 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2023 | 403 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2011 | 1081 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 4921 | 0.040 |
Why?
|
| Escherichia coli | 2 | 1991 | 4209 | 0.040 |
Why?
|
| Skin | 1 | 2013 | 4499 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 571 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2018 | 4847 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.040 |
Why?
|
| Radiography | 2 | 2007 | 6993 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1996 | 2934 | 0.040 |
Why?
|
| Incidence | 4 | 2014 | 21544 | 0.040 |
Why?
|
| Mitosis | 1 | 2022 | 1190 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1982 | 1169 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2001 | 555 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 594 | 0.030 |
Why?
|
| Asia | 1 | 2018 | 627 | 0.030 |
Why?
|
| Keratins | 1 | 2017 | 502 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20766 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2001 | 612 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1982 | 1748 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 130 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 1996 | 108 | 0.030 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 39405 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 165 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 751 | 0.030 |
Why?
|
| Sarcoma | 1 | 2006 | 1806 | 0.030 |
Why?
|
| Haplorhini | 1 | 1995 | 524 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2001 | 811 | 0.030 |
Why?
|
| Amyloidosis | 2 | 1992 | 879 | 0.030 |
Why?
|
| beta 2-Microglobulin | 2 | 1992 | 329 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 1265 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 2884 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 504 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11854 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 499 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1993 | 116 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 2046 | 0.030 |
Why?
|
| Metals | 1 | 1997 | 713 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 1386 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 706 | 0.030 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1996 | 391 | 0.020 |
Why?
|
| Remission Induction | 1 | 2018 | 2407 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2018 | 1595 | 0.020 |
Why?
|
| Cysts | 1 | 1997 | 685 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2010 | 2664 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 1794 | 0.020 |
Why?
|
| Amikacin | 1 | 1991 | 47 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2011 | 62 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2819 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 1996 | 5802 | 0.020 |
Why?
|
| Conjugation, Genetic | 1 | 1991 | 116 | 0.020 |
Why?
|
| Antigens, Neoplasm | 2 | 1996 | 1999 | 0.020 |
Why?
|
| Pathology, Veterinary | 1 | 2010 | 3 | 0.020 |
Why?
|
| DNA | 2 | 2022 | 7211 | 0.020 |
Why?
|
| Veterinarians | 1 | 2010 | 13 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2023 | 3334 | 0.020 |
Why?
|
| Venezuela | 1 | 1990 | 73 | 0.020 |
Why?
|
| Trimethoprim | 1 | 1990 | 79 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16716 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1997 | 1131 | 0.020 |
Why?
|
| Enterobacteriaceae | 1 | 1991 | 161 | 0.020 |
Why?
|
| Cat-Scratch Disease | 1 | 1989 | 23 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1748 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1996 | 1140 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2950 | 0.020 |
Why?
|
| Boston | 2 | 2014 | 9371 | 0.020 |
Why?
|
| Gentamicins | 1 | 1990 | 244 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14736 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 8562 | 0.020 |
Why?
|
| Bone Diseases | 1 | 1992 | 417 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 20224 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 848 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 749 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 962 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1992 | 554 | 0.020 |
Why?
|
| Cell Division | 1 | 1995 | 4478 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 4940 | 0.020 |
Why?
|
| Cell Line | 3 | 1995 | 15593 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1993 | 1395 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3794 | 0.020 |
Why?
|
| Young Adult | 3 | 2018 | 60048 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1221 | 0.020 |
Why?
|
| Carrier State | 1 | 1990 | 529 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2267 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13696 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10117 | 0.020 |
Why?
|
| Algorithms | 3 | 2011 | 14154 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 3846 | 0.020 |
Why?
|
| Male | 7 | 2022 | 364870 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 5408 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8628 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2013 | 54921 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 4031 | 0.010 |
Why?
|
| Rabbits | 1 | 2011 | 4782 | 0.010 |
Why?
|
| China | 1 | 1990 | 2389 | 0.010 |
Why?
|
| Massachusetts | 2 | 2011 | 8902 | 0.010 |
Why?
|
| Ki-67 Antigen | 2 | 1996 | 628 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1989 | 962 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1990 | 1955 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1996 | 2044 | 0.010 |
Why?
|
| Feces | 1 | 1990 | 1516 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22292 | 0.010 |
Why?
|
| Adolescent | 4 | 2018 | 89182 | 0.010 |
Why?
|
| Antibodies | 1 | 2011 | 2425 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 4250 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1992 | 1802 | 0.010 |
Why?
|
| Phosphoglycerate Kinase | 1 | 1982 | 66 | 0.010 |
Why?
|
| Butyric Acid | 1 | 1982 | 52 | 0.010 |
Why?
|
| Cross Infection | 1 | 1991 | 1422 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2862 | 0.010 |
Why?
|
| Histamine Antagonists | 1 | 1982 | 94 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2001 | 23 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 2003 | 6856 | 0.010 |
Why?
|
| Butyrates | 1 | 1982 | 168 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18472 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1982 | 251 | 0.010 |
Why?
|
| Vacuum | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cryoprotective Agents | 1 | 1982 | 128 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13646 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5916 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1982 | 209 | 0.010 |
Why?
|
| Electrophoresis, Disc | 1 | 1980 | 66 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 1280 | 0.010 |
Why?
|
| Azacitidine | 1 | 1982 | 335 | 0.010 |
Why?
|
| Animals | 5 | 2011 | 169322 | 0.010 |
Why?
|
| Pleura | 1 | 2001 | 248 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 6404 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1982 | 646 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2010 | 2348 | 0.010 |
Why?
|
| Automation | 1 | 2000 | 588 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3707 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 2226 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1980 | 1705 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1996 | 61 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 2229 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41791 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1996 | 183 | 0.010 |
Why?
|
| Reoperation | 1 | 2006 | 4340 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2003 | 1736 | 0.010 |
Why?
|
| Survival Rate | 2 | 2001 | 12870 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 3438 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1980 | 3092 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 11220 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1996 | 563 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 438 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1993 | 198 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 3529 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2000 | 1525 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1905 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1990 | 7458 | 0.010 |
Why?
|
| Premenopause | 1 | 1996 | 1039 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 17626 | 0.010 |
Why?
|
| Hip | 1 | 1992 | 255 | 0.010 |
Why?
|
| Operon | 1 | 1991 | 371 | 0.010 |
Why?
|
| Wrist | 1 | 1992 | 232 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1996 | 1337 | 0.010 |
Why?
|
| Shoulder | 1 | 1992 | 301 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1980 | 4175 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1991 | 187 | 0.010 |
Why?
|
| Klebsiella pneumoniae | 1 | 1991 | 253 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8730 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 2823 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 2205 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1991 | 830 | 0.000 |
Why?
|
| Prostatectomy | 1 | 1996 | 1841 | 0.000 |
Why?
|
| Infant | 1 | 1990 | 36512 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1748 | 0.000 |
Why?
|
| Child | 2 | 2001 | 80894 | 0.000 |
Why?
|
| DNA Transposable Elements | 1 | 1991 | 762 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 42654 | 0.000 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 1083 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6084 | 0.000 |
Why?
|
| Comorbidity | 1 | 2001 | 10588 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12801 | 0.000 |
Why?
|
| Shoulder Joint | 1 | 1992 | 749 | 0.000 |
Why?
|
| Spine | 1 | 1992 | 1141 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1980 | 19019 | 0.000 |
Why?
|
| Recurrence | 1 | 1996 | 8501 | 0.000 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 1640 | 0.000 |
Why?
|
| Mice | 2 | 1982 | 82004 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12421 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 13425 | 0.000 |
Why?
|
| Lung | 1 | 2001 | 10087 | 0.000 |
Why?
|
| Alleles | 1 | 1991 | 6892 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2001 | 24316 | 0.000 |
Why?
|
| Pain | 1 | 1992 | 5102 | 0.000 |
Why?
|